Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Technology Industry News Can usage-based pricing unlock mass adoption of enterprise AI agents—or will complexity kill scale? Salesforce and Microsoft are betting on usage-based pricing to scale AI agent adoption. Can this model deliver predictable value, or will it hinder enterprise growth? byPallavi MadhirajuJuly 9, 2025